Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Park Avenue Securities LLC

Park Avenue Securities LLC decreased its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 29.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 83,068 shares of the company’s stock after selling 35,000 shares during the period. Park Avenue Securities LLC owned about 0.08% of Annexon worth $160,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in Annexon in the 4th quarter valued at about $59,000. CANADA LIFE ASSURANCE Co acquired a new position in Annexon in the fourth quarter worth approximately $77,000. E Fund Management Co. Ltd. increased its holdings in Annexon by 36.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after buying an additional 4,086 shares during the last quarter. Forefront Analytics LLC grew its holdings in Annexon by 56.8% during the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after purchasing an additional 5,950 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Annexon in the fourth quarter valued at approximately $98,000.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Needham & Company LLC lowered their target price on Annexon from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. HC Wainwright dropped their price objective on Annexon from $20.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th.

Annexon Price Performance

Annexon stock opened at $2.44 on Tuesday. Annexon, Inc. has a one year low of $1.29 and a one year high of $7.85. The stock’s 50 day moving average is $1.95 and its 200 day moving average is $3.06. The firm has a market cap of $267.70 million, a P/E ratio of -2.32 and a beta of 1.26.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Equities analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.